Replimune Group (NASDAQ:REPL) Shares Up 6.2% - Should You Buy?

Key Points

• Shares jumped 6.2% to $6.275 on Friday (intraday high $6.39) on light volume of 486,769 shares, about 71% below the average session volume.
• Analyst views are mixed: Wedbush and Piper Sandler recently raised targets to $19 and $14, but the MarketBeat consensus remains a "Hold" with a $10 price target (six Buys, two Holds, two Sells).
• Replimune is a clinical‑stage biotech with negative earnings (Q EPS -$0.77, slightly beating estimates), a market cap of ~$394M, high liquidity ratios and ~92.5% institutional ownership, and an insider sold 6,500 shares under a 10b5‑1 plan.

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report)'s share price shot up 6.2% on Friday . The company traded as high as $6.39 and last traded at $6.2750. 486,769 shares changed hands during trading, a decline of 71% from the average session volume of 1,676,120 shares. The stock had previously closed at $5.91.

Wall Street Analyst Weigh In

REPL has been the subject of a number of recent analyst reports. Wedbush increased their price objective on Replimune Group from $18.00 to $19.00 and gave the stock an "outperform" rating in a report on Wednesday, February 4th. Weiss Ratings reissued a "sell (d-)" rating on shares of Replimune Group in a research note on Monday, December 29th. Finally, Piper Sandler increased their target price on Replimune Group from $13.00 to $14.00 and gave the company an "overweight" rating in a report on Thursday, February 5th. Six equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $10.00.

Replimune Group Stock Down 19.3%

The business has a 50-day simple moving average of $7.56 and a two-hundred day simple moving average of $7.89. The company has a market cap of $393.94 million, a price-to-earnings ratio of -1.39 and a beta of 0.74. The company has a quick ratio of 5.60, a current ratio of 5.60 and a debt-to-equity ratio of 0.33.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported ($0.77) EPS for the quarter, topping analysts' consensus estimates of ($0.85) by $0.08. As a group, equities analysts forecast that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Replimune Group news, insider Christopher Sarchi sold 6,500 shares of Replimune Group stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $8.01, for a total transaction of $52,065.00. Following the sale, the insider directly owned 151,588 shares of the company's stock, valued at approximately $1,214,219.88. The trade was a 4.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 5.20% of the company's stock.

Institutional Investors Weigh In On Replimune Group

Institutional investors have recently added to or reduced their stakes in the stock. International Assets Investment Management LLC acquired a new stake in Replimune Group during the fourth quarter valued at approximately $29,000. CWM LLC boosted its holdings in Replimune Group by 248.6% during the fourth quarter. CWM LLC now owns 4,047 shares of the company's stock valued at $39,000 after purchasing an additional 2,886 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in Replimune Group by 37.5% during the second quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company's stock valued at $64,000 after purchasing an additional 1,879 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Replimune Group during the second quarter valued at approximately $69,000. Finally, Russell Investments Group Ltd. boosted its holdings in Replimune Group by 3,638.9% during the third quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company's stock valued at $33,000 after purchasing an additional 7,569 shares in the last quarter. 92.53% of the stock is owned by institutional investors and hedge funds.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company's proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune's lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.